FSCDR 2026 at a glance
FSCDR 2026 will examine how sickle cell disease (SCD) strategy is evolving beyond clinical efficacy toward trial endpoints, treatment access and real-world implementation. From hemoglobin-focused therapies and emerging biomarkers to gene therapy readiness and pain management, the symposium will highlight developments that could influence clinical differentiation and competitive positioning.
📅 Build your schedule around the topics that matter most.
📥 Download the FSCDR 2026_Preview_by_LucidQuest
FSCDR 2026: Key Developments in Sickle Cell Disease
Hemoglobin Biology: Emerging Therapies and Competitive Differentiation
Etavopivat, osivelotor, pociredir, voxelotor analyses and curcumin will keep hemoglobin-focused strategies central to discussions about therapeutic development and competitive positioning in sickle cell disease.
Clinical Endpoints and Biomarkers: Defining Treatment Benefit
Discussions involving the FDA, CSL, Agios, Functional Fluidics and Virginia Commonwealth University (VCU) may influence how sickle cell disease trials assess treatment benefit.
Key considerations include pain, vaso-occlusive crises (VOCs), organ damage and patient-reported outcomes (PROs).
Gene Therapy Readiness: Access and Real-World Implementation
Exa-cel benchmarking and LYFGENIA patient-journey discussions will bring greater attention to the practical requirements of gene therapy delivery.
Access logistics, nursing readiness, patient navigation and monitoring will be important considerations alongside clinical efficacy.
Sickle Cell Pain Management: Distinguishing Development Strategies
Acute vaso-occlusive episode (VOE) biology, chronic pain measurement, opioid optimization and non-pharmacologic interventions will highlight the need to distinguish between different pain management and treatment development strategies.
Sickle Cell Disease Competitive Landscape: Industry and Competitor Signals
Novo Nordisk’s Etavopivat: Disease Modification and Organ Protection
HIBISCUS 2, HIBISCUS Kids and end-organ damage analyses will test the broader disease-modification and organ-protection positioning of Novo Nordisk’s etavopivat.
Osivelotor and Voxelotor: Addressing Evidence and Confidence Gaps
Hemoglobin polymerization inhibition will remain an important area of discussion.
Osivelotor and voxelotor analyses will highlight questions surrounding safety, durability and real-world effectiveness that are relevant to confidence in this therapeutic approach.
Pociredir: Evaluating Early Clinical Signals
Phase 1b PIONEER data for pociredir will provide further insight into fetal hemoglobin (HbF), hemoglobin, hemolysis and safety signals in severe sickle cell disease.
CSL’s Anumigilimab and CSL889: Targeting Inflammation and VOC Biology
Discussions of anumigilimab and CSL889 will explore inflammation and vaso-occlusive crisis biology as potential therapeutic development pathways.
The maturity of the supporting evidence remains a key consideration for assessing their competitive potential.
What We Are Watching After FSCDR 2026
LucidQuest will monitor three strategic developments:
Oral disease-modifying therapies: Whether stronger safety, durability and endpoint evidence can rebuild confidence in oral treatment strategies.
Gene therapy competition: Whether treatment center readiness and patient navigation become increasingly important competitive differentiators beyond pivotal trial efficacy.
Screening and access: Whether Gazelle, RECIPE and stigma-reduction interventions demonstrate operational value beyond academic settings.
Download LucidQuest’s FSCDR 2026 Preview Report
Download our FSCDR 2026 preview report for deeper analysis of emerging sickle cell disease therapies, clinical development strategies and competitive dynamics.
📅 Build your schedule around the sessions that matter most.
📥 Download the FSCDR 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
